[go: up one dir, main page]

DE60007592D1 - Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren - Google Patents

Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren

Info

Publication number
DE60007592D1
DE60007592D1 DE60007592T DE60007592T DE60007592D1 DE 60007592 D1 DE60007592 D1 DE 60007592D1 DE 60007592 T DE60007592 T DE 60007592T DE 60007592 T DE60007592 T DE 60007592T DE 60007592 D1 DE60007592 D1 DE 60007592D1
Authority
DE
Germany
Prior art keywords
pyrrolylamides
bicyclic
glycogen phosphorylase
phosphorylase inhibitors
prodrugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60007592T
Other languages
English (en)
Other versions
DE60007592T2 (de
Inventor
Daisy Joe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60007592D1 publication Critical patent/DE60007592D1/de
Publication of DE60007592T2 publication Critical patent/DE60007592T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60007592T 1999-09-30 2000-09-18 Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren Expired - Fee Related DE60007592T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15714899P 1999-09-30 1999-09-30
US157148P 1999-09-30

Publications (2)

Publication Number Publication Date
DE60007592D1 true DE60007592D1 (de) 2004-02-12
DE60007592T2 DE60007592T2 (de) 2004-09-16

Family

ID=22562529

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60007592T Expired - Fee Related DE60007592T2 (de) 1999-09-30 2000-09-18 Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren

Country Status (10)

Country Link
US (3) US6399601B1 (de)
EP (1) EP1088824B1 (de)
JP (1) JP3489819B2 (de)
AT (1) ATE257480T1 (de)
BR (1) BR0004582A (de)
CA (1) CA2321379A1 (de)
DE (1) DE60007592T2 (de)
DK (1) DK1088824T3 (de)
ES (1) ES2211454T3 (de)
PT (1) PT1088824E (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69838916T2 (de) 1997-11-14 2008-12-18 Amylin Pharmaceuticals, Inc., San Diego Neuartige exendin agonisten
US7223725B1 (en) * 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7338955B1 (en) * 1999-10-12 2008-03-04 Lilly Icos Llc Medicament for treatment of neuropathies
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
AU4116801A (en) * 2000-03-17 2001-09-24 Ajinomoto Kk Drugs for complications of diabetes and neuropathy and utilization thereof
EP1136071A3 (de) * 2000-03-22 2003-03-26 Pfizer Products Inc. Verwendung von Glykogen-Phosphorylase-Hemmern
US20020165237A1 (en) * 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
WO2002013798A2 (en) * 2000-08-11 2002-02-21 Pfizer Limited Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
WO2002034285A2 (en) 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
CA2436576A1 (en) * 2001-02-02 2002-08-08 Pfizer Inc. Treatment of diabetes mellitus using vardenafil
CA2457836A1 (en) * 2001-08-23 2003-03-06 Mitsubishi Pharma Corporation Preventive and/or remedial agent for disease attributable to arteriosclerotic activity
EP1452526A1 (de) * 2001-10-29 2004-09-01 Japan Tobacco Inc. Indolverbindung und deren medizinische verwendung
JP2005516968A (ja) * 2001-12-29 2005-06-09 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１化合物と糖尿病後期合併症モジュレーターの組み合わせ使用
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
AU2003227360A1 (en) * 2002-04-25 2003-11-10 Yamanouchi Pharmaceutical Co., Ltd. Novel amide derivatives or salts thereof
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
JP4596915B2 (ja) 2002-09-06 2010-12-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チエノピロリルおよびフラノピロリル化合物並びにヒスタミンｈ４受容体リガンドとしてのそれらの使用
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
BR0316099A (pt) 2002-11-07 2005-09-27 Pfizer Prod Inc Agentes antidiabéticos
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
WO2004043491A1 (ja) * 2002-11-14 2004-05-27 Ono Pharmaceutical Co., Ltd. 脊柱管狭窄症治療剤
AU2003283216A1 (en) * 2002-12-03 2004-06-23 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
AU2004212004B2 (en) * 2003-02-13 2008-01-10 Albert Einstein College Of Medicine Of Yeshiva University Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
CA2521915A1 (en) * 2003-04-15 2004-10-28 Pfizer Inc. Alpha substituted carboxylic acid as ppar modulators
MXPA05011176A (es) * 2003-04-17 2005-12-14 Pfizer Prod Inc Derivados de carboxamida como agentes antidiabeticos.
EP1633709A1 (de) * 2003-04-30 2006-03-15 Pfizer Products Inc. Verbindungen zur verwendung als anti-diabetika
ATE473974T1 (de) * 2003-05-21 2010-07-15 Prosidion Ltd Pyrrolopyridin-2-carbonsäuren als hemmer der glycogenphosphorylase
US7405210B2 (en) * 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
CN100480249C (zh) * 2003-05-21 2009-04-22 普罗西迪恩有限公司 作为糖原磷酸化酶抑制剂的吡咯并吡啶-2-甲酸酰胺
WO2004113345A1 (ja) * 2003-06-20 2004-12-29 Japan Tobacco Inc. 縮合ピロール化合物及びその医薬用途
PL380887A1 (pl) 2003-12-29 2007-04-02 Sepracor Inc. Pirolowe i pirazolowe inhibitory DAAO
ATE483708T1 (de) 2004-03-08 2010-10-15 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
WO2005115379A2 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
EP1891971A4 (de) * 2005-01-31 2010-02-03 Ajinomoto Kk Medizinische zusammensetzung mit hyperglykämiemittel zur linderung oder behandlung von glucose-intoleranz, borderline-diabetes, insulinresistenz und hyperinsulinämie
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
CA2614282A1 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
AU2007205114B2 (en) 2006-01-06 2012-11-08 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
CA2636275C (en) 2006-01-06 2013-02-12 Sepracor Inc. Tetralone-based monoamine reuptake inhibitors
AU2007233041B2 (en) 2006-03-31 2013-05-02 Sepracor Inc. Preparation of chiral amides and amines
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
KR20090024823A (ko) * 2006-06-30 2009-03-09 세프라코 아이엔시. Ｄ-아미노산 옥시다제의 융합된 헤테로사이클 억제제
US20080058395A1 (en) * 2006-06-30 2008-03-06 Sepracor Inc. Fused heterocyclic inhibitors of D-amino acid oxidase
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
WO2008047821A1 (en) 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
US20090099248A1 (en) * 2007-01-18 2009-04-16 Sepracor Inc. Inhibitors of d-amino acid oxidase
AU2008259841B2 (en) 2007-05-31 2015-02-05 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
US20100152200A1 (en) * 2008-11-17 2010-06-17 The Regents Of The University Of Michigan Alphavirus inhibitors and uses thereof
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2013133685A1 (en) 2012-03-09 2013-09-12 Biotropics Malaysia Berhad Extract formulations of rhodamnia cinerea and uses thereof
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
GB201708451D0 (en) * 2017-05-26 2017-07-12 Univ Oxford Innovation Ltd Inhibitors of metallo-beta-lactamases
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
WO2019221192A1 (ja) 2018-05-15 2019-11-21 旭化成株式会社 アミノ酸アミノアルキルエステル又はその無機酸塩の製造方法
CN111468183A (zh) * 2019-11-25 2020-07-31 天津大学 多氟代三芳基手性螺环磷酸催化剂及其制备方法、用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0031088A1 (de) * 1979-12-19 1981-07-01 Hoechst Aktiengesellschaft Benzolsulfonylharnstoffe, Verfahren zu ihrer Herstellung, pharmazeutische Präparate auf Basis dieser Verbindungen sowie ihre Verwendung
ES2081747B1 (es) * 1993-09-07 1997-01-16 Esteve Labor Dr Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos.
FR2733750B1 (fr) * 1995-05-03 1997-06-13 Synthelabo Derives de l'acide gamma-oxo-alpha-(phenylmethyl)-5,6- dihydro-4h-thieno(3,4-c)pyrrole-5-butanoique, leur preparation et leur application en therapeutique
DK0832066T3 (da) * 1995-06-06 2001-11-19 Pfizer Substituerede N-(indol-2-carbonyl)amider og derivater som glycogenphosphorylaseinhibitorer
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US5939417A (en) * 1998-10-19 1999-08-17 Cell Pathways Inc 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia

Also Published As

Publication number Publication date
BR0004582A (pt) 2001-04-17
ES2211454T3 (es) 2004-07-16
US6399601B1 (en) 2002-06-04
PT1088824E (pt) 2004-04-30
ATE257480T1 (de) 2004-01-15
EP1088824B1 (de) 2004-01-07
JP2001131181A (ja) 2001-05-15
US20020183369A1 (en) 2002-12-05
EP1088824A2 (de) 2001-04-04
DK1088824T3 (da) 2004-04-13
DE60007592T2 (de) 2004-09-16
US20030195361A1 (en) 2003-10-16
EP1088824A3 (de) 2001-06-27
US6828343B2 (en) 2004-12-07
CA2321379A1 (en) 2001-03-30
US6576653B2 (en) 2003-06-10
JP3489819B2 (ja) 2004-01-26

Similar Documents

Publication Publication Date Title
ATE257480T1 (de) Bicyclische pyrrolylamide als glycogenphosphorylase-inhibitoren
MXPA05011702A (es) Agentes antidiabeticos.
DE602004028122D1 (de) Pyrrolopyridin-2-carbonsäuren als hemmer der glycogenphosphorylase
BR0300314A (pt) Agentes antidiabéticos
ATE303387T1 (de) Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus
DE60330757D1 (de) Verwendung von pyridylamiden als angiogenesehemmer
AP1808A (en) Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine.
WO2006046039A3 (en) Tetracyclic indole derivatives as antiviral agents
DE60315336D1 (de) Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv)
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
NO20032261D0 (no) Medisinske preparater
ATE453389T1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
WO2006059164A3 (en) Pyrrolopyridine-2-carboxylic acid amides
WO2007039883A3 (en) Process for preparation of aprepitant
BRPI0607214A2 (pt) derivados de 2-(4-cianofenilamino) pirimidina inibidores de hiv
DK1634595T3 (da) N-Phenylbenzamidderivater som medikamenter til behandling af kronisk obstruktiv lungesygdom (KOL)
WO2007020411A8 (en) Amide derivatives
IL147348A0 (en) Tricyclic compounds having spiro union
EP1914229A4 (de) Neuartige cercosporamidderivate
IL169577A0 (en) Oligosaccharide derivatives and pharmaceutical compostions containing the same
NO20042881L (no) Substituerte cykloheksan-derivater
TW200642686A (en) Aporphine or secoaporphine compounds for treatment of diabetes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee